| 武金银.孟鲁司特钠与布地奈德对儿童咳嗽变异性哮喘血清肿瘤坏死因子-α、免疫球蛋白E水平变化分析[J].安徽医药,2018,22(4):750-752. |
| 孟鲁司特钠与布地奈德对儿童咳嗽变异性哮喘血清肿瘤坏死因子-α、免疫球蛋白E水平变化分析 |
| Effect of montelukast and budesonide on serum TNF-α and IgE in children with cough variant asthma |
| 投稿时间：2016-11-23 |
| DOI： |
| 中文关键词: 孟鲁司特钠 布地奈德 咳嗽变异性哮喘 儿童 肿瘤坏死因子-α 免疫球蛋白E |
| 英文关键词: montelukast budesonide cough variant asthma children TNF-α IgE |
| 基金项目: |
|
| 摘要点击次数: 2410 |
| 全文下载次数: 669 |
| 中文摘要: |
| 目的 探讨孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘(CVA)的效果,以及对血清肿瘤坏死因子-α(TNF-α)、免疫球蛋白E(IgE)的影响。方法 选取2014年3月—2016年3月在该院治疗的CVA患儿110例,将患儿随机分为观察组(n=59)和对照组(n=51),观察组给予孟鲁司特钠联合布地奈德治疗,对照组给予布地奈德治疗,观察两组治疗效果,以及血清TNF-α和IgE变化等。结果 观察组治疗效果明显优于对照组(P＜0.05),其总有效率为96.61%；观察组咳嗽消失时间和喘憋消失时间分别为(7.20±1.59)d和(8.12±1.22)d,明显短于对照组(P＜0.05)；观察组治疗后TNF-α和IgE分别为(520.05±98.92)ng·L-1和(610.01±101.29)U·mL-1,明显低于对照组(P＜0.05)；观察组治疗后用力肺活量(FVC)和第1秒用力呼气量(FEV1)分别为(3.97±0.62)L和(3.01±0.50)L,明显高于对照组(P＜0.05)。结论 鲁司特钠联合布地奈德治疗儿童CVA有较好的效果,能明显降低血清TNF-α和IgE水平,改善患儿肺功能。 |
| 英文摘要: |
| Objective To investigate the effect of montelukast combined with budesonide in the treatment of children with cough variant asthma (CVA) and its effect on serum tumor necrosis factor-α(TNF-α),immunoglobulin E (IgE). Methods From March 2014 to March 2016,0 cases of children with CVA in our hospital were selected and randomly divided into observation group (n=59) and control group (n=51).The observation group was treated with montelukast combined with budesonide treatment,and the control group was given budesonide treatment only.And then two groups therapeutic effect and the serum levels of TNF-α and IgE etc were observed. Results The treatment effect of the observation group was significantly better than that of the control group (P<0.05),the total effective rate was 96.61%.The disappearance time of cough and wheezes in the observation group was (7.20±1.59) d and (8.12±1.22) d,which was significantly shorter than the control group (P<0.05).The observation group after treatment TNF-α and IgE were (520.05±98.92) ng·L-1 and (610.01±101.29) U·mL-1,significantly lower than the control group (P<0.05).The forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) in the observation group after treatment were (3.97±0.62) L and (3.01±0.50) L,significantly higher than that in the control group (P<0.05).Conclusions Montelukast combined with budesonide in the treatment of children with CVA has a good effect,can significantly reduce the serum levels of IgE and TNF-α,improve pulmonary function in children. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
